[1]季春影 张瑞英.心力衰竭与心肌线粒体代谢[J].心血管病学进展,2020,(1):63-66.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.017]
 JI ChunyingZHANG Ruiying.Heart Failure and Myocardial Mitochondrial Metabolism[J].Advances in Cardiovascular Diseases,2020,(1):63-66.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.017]
点击复制

心力衰竭与心肌线粒体代谢()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年1期
页码:
63-66
栏目:
综述
出版日期:
2020-02-04

文章信息/Info

Title:
Heart Failure and Myocardial Mitochondrial Metabolism
作者:
季春影1 张瑞英2
(1.哈尔滨医科大学附属第一医院,黑龙江 哈尔滨 150001;2.哈尔滨医科大学附属第一医院内科危重症,黑龙江 哈尔滨 150001)
Author(s):
JI Chunying1ZHANG Ruiying2
(1.The First Affiliated Hospital of Harbin Medical University,Harbin 150001 Heilongjiang,China;2.Medical Critical Care Unit ,The First Affiliated Hospital of Harbin Medical University,Harbin 150001 ,Heilongjiang,China)
关键词:
心力衰竭能量代谢线粒体氧化应激
Keywords:
Heart failure Energy metabolism Mitochondria Oxidative stress
DOI:
10.16806/j.cnki.issn.1004-3934.2020.01.017
摘要:
心力衰竭作为各种心脏疾病的严重表现或晚期阶段,是影响中国国民健康及社会经济的严重疾病之一;尽管治疗手段不断改进,心力衰竭的病死率和再住院率仍较高,需对其病生理进行深入研究。近年来的研究更加关注心力衰竭与心肌线粒体生物代谢的关系,其中包括线粒体的动态平衡、代谢、氧化应激和线粒体代谢相关信号分子等,线粒体有望成为心力衰竭治疗的新靶点。现阐述心力衰竭时能量代谢与心肌线粒体的关系以及心力衰竭治疗中线粒体靶向治疗的重要性。
Abstract:
As a serious manifestation or late stage of various heart diseases, heart failure is one of the serious diseases affecting the national health and social economy of China. Despite the continuous improvement of treatment methods,the mortality rate a nd rehospitalization rate of heart failure are still high,and it needs to be in-depth study of pathophysiology.In recent years,studies have focused more on the relationship between heart failure and myocardial mitochondrial biological metabolism,including mitochondrial dynamic balance,metabolism,oxidative stress and mitochondrial metabolism-related signaling molecules.Mitochondria are expected to become a new target for the treatment of heart failure.This article will describe the relationship between energy metabolism and myocardial mitochondria in heart failure and the importance of mitochondria-targeted therapy in the treatment of heart failure.

参考文献/References:

[1].Abate M,Festa A,Falco M,et al. Mitochondria as playmakers of apoptosis,autophagy and senescence[J]. Semin Cell Dev Biol,2019,?pii:S1084-9521(18)30187-3.
[2].Rosca MG,Tandler B,Hoppel CL. Mitochondria in cardiac hypertrophy and heart failure[J]. J Mol Cell Cardiol,2013,55:31-41
[3].Wai T,Langer T. Mitochondrial dynamics and metabolic regulation[J]. Trends Endocrinol Metab,2016,27(2):105-117.
[4].Leonardo AM. Energy metabolism in cardiac remodeling and heart failure[J]. Cardiol Rev,
[5].2013 ,21(3):135-140.
[6].Fragasso G,Salerno A,Lattuada G,et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure[J]. Heart,2011,97(18):1495-1500.
[7].Jain A,Atale N,Kohli S,et al. An assessment of norepinephrine mediated hypertrophy to apoptosis transition in cardiac cells:a signal for cell death[J]. Chem Biol Interact,2015,225:54-62.
[8].Bertero E,Maack C. Calcium Signaling and Reactive Oxygen Species in Mitochondria[J]. Circ Res,2018,122(10):1460-1478.
[9].Deshwal S,Di Sante M,Di Lisa F,et al. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease[J]. Curr Opin Pharmacol,2017,33:64-69.
[10].Lebrecht D,Kokkori A,Ketelsen UP,et al. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin[J]. J Pathol,2005,207:436-444.
[11].Miyata N,Goda N,Matsuo K. Cooperative function of Fmp30,Mdm31,and Mdm32 in Ups1-independent cardiolipin accumulation in the yeast Saccharomyces cerevisiae[J]. Sci Rep,2017,7(1):16447.
[12].Kameoka S,Adachi Y,Okamoto K,et al. Phosphatidic acid and cardiolipin coordinate mitochondrial dynamics[J]. Trends Cell Biol,2018,28(1):67-76.
[13].Zhang Y,Guallar E,Ashar FN,et al. Association between mitochondrial DNA copy number and sudden cardiac death:findings from the Atherosclerosis Risk in Communities study (ARIC)[J]. Eur Heart J,2017,38(46):3443-3448.
[14].Chen Y,Liu Y,Gerald W. Dorn. Mitochondrial fusion is essential for organelle function and
[15].cardiac homeostasis[J]. Circ Res,2011,109(12):1327-1331.
[16].Bernhardt D,Müller M,Reichert AS,et al. Simultaneous impairment of mitochondrial fission and fusion reduces mitophagy and shortens replicative lifespan[J]. Sci Rep,2015,5:7885.
[17].Yang H,Shen H,Li J,et al. SIGMAR1/Sigma-1 receptor ablation impairs autophagosome clearance.[J]. Autophagy,2019,15(9):1539-1557.
[18].Huang CY,Lai CH,Kuo CH,et al. Inhibition of ERK-Drp1 signaling and mitochondria fragmen-tation alleviates IGF-IIR-induced mitochondria dysfunction during heart failure[J]. J Mol Cell Cardiol,2018,122:58-68.
[19].Sato T,Kadowaki A,Suzuki T,et al. Loss of Apelin Augments AngiotensinⅡ-Induced Cardiac Dysfunction and Pathological Remodeling[J]. Int J Mol Sci,2019,20(2).?pii: E239.
[20].Tian HP,Sun YH,He L,et al. Single-stranded DNA-binding protein 1 abrogates cardiac fibro-blast proliferation and collagen expression induced by angiotensinⅡ[J]. Int Heart J.2018,59(6):1398-1408.
[21].Kumar S,Wang G,Zheng N,et al. HIMF(hypoxia-induced mitogenic factor)-IL(interleukin)-6 signaling mediates cardiomyocyte-fibroblast crosstalk to promote cardiac hypertrophy and fi-
[22].brosis[J]. Hypertension,2019,73(5):1058-1070.
[23].Umbarawan Y,Syamsunarno MRAA,Koitabashi N,et al. Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure[J]. Sci Rep.2018,8(1):12035.
[24].Kalpage HA,Bazylianska V,Recanati MA,et al. Tissue-specific regulation of cytochrome c by post-translational modifications:respiration,the mitochondrial membrane potential,ROS,and apoptosis[J]. FASEB J,2019,33(2):1540-1553.
[25].Quryshi N,Norwood Toro LE,Ait-Aissa K,et al. Chemotherapeutic-induced cardiovascular dysfunction:physiological effects,early detection—the role of telomerase to counteract mitochondrial defects and oxidative stress[J]. Int J Mol Sci,2018,19(3).pii: E797.
[26].Anderson R,Lagnado A,Maggiorani D.Maggiorani,Damien,et al, Length-independent telomere damage drives post-mitotic cardiomyocyte senescence[J]. EMBO J,2019,38(5).pii: e100492.
[27].Hafner AV,Dai J,Gomes AP,et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy[J]. Aging (Albany NY),2010,2(12):914-923.
[28].Karbowska J,Kochan Z,Smoleński,et al. Peroxisome proliferator-activated receptor alpha is
[29].downregulated in the failing human heart[J]. Cell Mol Biol Lett,2003,8(1):49-53.
[30].Jia G,Hill MA,Sowers JR. Diabetic Cardiomyopathy:An Update of Mechanisms Contributing to This Clinical Entity[J]. Circ Res.2018,122(4):624-638.
[31].Chen P,Zhan Q,Bai Y,et al. Serum Peroxisome proliferator-activated receptor gamma coact-ivator-1α related to myocardial energy expenditure in patients with chronic heart failure[J].
[32].Am J Med Sci,2019,357(3):205-212.
[33].Leucker TM,Bienengraeber M,Muravyeva M,et al. Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection[J]. Mol Cell Cardiol,2011,51(5):803-811.
[34].Matsuhashi T,Sato T,Kanno SI,et al. Mitochonic acid 5(MA-5) facilitates ATP synthase oligomerization and cell survival in various mitochondrial diseases[J]. EBioMedicine,2017,20:27-38.
[35].Sharma A,Stevens SR,Lucas J,et al. Utility of growth differentiation factor-15,a?marker of oxidative stress and inflammation,in chronic heart failure:insights from the HF-ACTION study[J]. JACC Heart Fail,2017,5(10):724-734.
[36].Yatsuga S,Fujita Y,Ishii A,et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders[J]. Ann Neurol,2015,78(5):814-823.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
 DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
 LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(1):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
 ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(1):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
 LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(1):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
 KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(1):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
 SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(1):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
 XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
 GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(1):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
 HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
 WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(1):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

备注/Memo

备注/Memo:
基金项目:哈尔滨市科技创新人才基金(2017RAXXJ064)
更新日期/Last Update: 2020-03-24